Table 2 Changes in levels of cardiac function before and after four weeks treatment between the TEA group and control group
From: Effects of thoracic epidural analgesia on plasma cAMP and cGMP levels in patients with heart failure
GROUP | LVEDD (mm) | 95% CI | EF (%) | 95% CI | FS (%) | 95% CI | NYHA | 95% CI |
|---|---|---|---|---|---|---|---|---|
Control group | ||||||||
Pre-treatment | 64.85 ± 5.86 | (53.56-76.13) | 32.45 ± 7.21 | (18.31-46.59) | 25.80 ± 5.73 | (14.56-37.04) | 3.65 ± 0.48 | (2.69-4.61) |
post-treatment | 63.15 ± 5.23 | (52.89-73.40) | 33.15 ± 5.98 | (21.44-44.86) | 26.61 ± 5.52 | (15.73-37.37) | 3.3 ± 0.8 | (1.73-4.87) |
Chang | 1.65 ± 0.64 | 0.55 ± 0.38 | 0.85 ± 0.61 | 0.35 ± 0.10 | ||||
TEA group | ||||||||
Pre-treatment | 66.45 ± 5.28 | (56.08-76.80) | 30.35 ± 6.78 | (13.23-46.78) | 24.20 ± 3.54 | (17.24-31.15) | 3.75 ± 0.44 | (2.87-4.62) |
post-treatment | 58.30 ± 5.38 | (47.75-68.64) | 34.15 ± 6.12 | (16.39-50.42) | 28.15 ± 4.67 | (18.99-37.30) | 2.55 ± 0.76 | (1.06-4.04) |
Chang | 8.15 ± 0.65** | 3.80 ± 0.56** | 3.95 ± 0.62** | 1.2 ± 0.16** |